ym 529 has been researched along with Lung Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawaguchi, T; Kawai, N; Nakazawa, T; Taniguchi, S; Tojo, T; Tsujimura, T; Yasukawa, M | 1 |
| Goto, H; Kanematsu, T; Miki, T; Muguruma, H; Sone, S; Uehara, H; Yano, S; Zhang, H | 1 |
| Goto, H; Hanibuchi, M; Miki, T; Sone, S; Uehara, H; Yano, S; Zhang, H | 1 |
| Kimura, S; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T | 1 |
| Aoe, M; Date, H; Hara, F; Koshimune, R; Ouchida, M; Sano, Y; Shimizu, N; Tokumo, M; Toyooka, S | 1 |
5 other study(ies) available for ym 529 and Lung Neoplasms
| Article | Year |
|---|---|
Minodronic Acid in Combination with γδT Cells Induces Apoptosis of Non-small Cell Lung Carcinoma Cell Lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transplantation; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Receptors, Antigen, T-Cell, gamma-delta | 2016 |
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Small Cell; Cell Division; Diphosphonates; Drug Combinations; Etoposide; Humans; Imidazoles; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoclasts; Parathyroid Hormone-Related Protein; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2003 |
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Cisplatin; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Paclitaxel; Protein Prenylation; rap1 GTP-Binding Proteins; ras Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Lung Neoplasms | 2007 |